- Home
- LGCL vs CTSO Comparison
LGCL vs CTSO Comparison
Compare LGCL & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- CTSO
- Stock Information
- Founded
- LGCL 2009
- CTSO 1997
- Country
- LGCL China
- CTSO United States
- Employees
- LGCL N/A
- CTSO N/A
- Industry
- LGCL
- CTSO Medical/Dental Instruments
- Sector
- LGCL
- CTSO Health Care
- Exchange
- LGCL NYSE
- CTSO Nasdaq
- Market Cap
- LGCL 44.3M
- CTSO 48.2M
- IPO Year
- LGCL 2024
- CTSO N/A
- Fundamental
- Price
- LGCL $0.48
- CTSO $0.92
- Analyst Decision
- LGCL
- CTSO Strong Buy
- Analyst Count
- LGCL 0
- CTSO 3
- Target Price
- LGCL N/A
- CTSO $4.67
- AVG Volume (30 Days)
- LGCL 401.3K
- CTSO 141.5K
- Earning Date
- LGCL 11-22-2024
- CTSO 11-07-2024
- Dividend Yield
- LGCL N/A
- CTSO N/A
- EPS Growth
- LGCL 11.49
- CTSO N/A
- EPS
- LGCL 0.14
- CTSO N/A
- Revenue
- LGCL $173,306,912.00
- CTSO $37,739,531.00
- Revenue This Year
- LGCL N/A
- CTSO $8.08
- Revenue Next Year
- LGCL N/A
- CTSO $12.80
- P/E Ratio
- LGCL $3.52
- CTSO N/A
- Revenue Growth
- LGCL N/A
- CTSO 1.80
- 52 Week Low
- LGCL $0.47
- CTSO $0.70
- 52 Week High
- LGCL $5.00
- CTSO $1.88
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- CTSO 49.38
- Support Level
- LGCL N/A
- CTSO $0.80
- Resistance Level
- LGCL N/A
- CTSO $1.09
- Average True Range (ATR)
- LGCL 0.00
- CTSO 0.09
- MACD
- LGCL 0.00
- CTSO 0.00
- Stochastic Oscillator
- LGCL 0.00
- CTSO 39.24
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.